Fractyl Health, Inc. GUTS 深 沪
等待开盘 08-05 09:30:00 美东时间
1.86
+0.050
+2.76%
华盛通- 最 高1.92
- 今 开1.81
- 成交量 11.14万股
- 最 低 1.766
- 昨 收 1.81
- 总市值 9109.65万
- 52周最高 3.72
- 市盈率 静 --
- 换手率 0.23%
- 52周最低 0.873
- 委 比 71.69%
- 总股本 4897.66万
- 历史最高 14.50
- 量 比 0.54
- 振 幅 8.51%
- 历史最低 0.873
- 每 手 1
- 风险率 0.57%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Fractyl Health Reports Positive 3-Month REVEAL-1 Cohort Data Showing Revita® Sustained Weight Loss After GLP-1 Discontinuation, Supporting its Potential as a First-in-Class Weight Maintenance Therapy
Fractyl Health announced positive 3-month data from the REVEAL-1 Cohort of its REMAIN-1 pivotal study, showing Revita may help maintain or further reduce weight after discontinuing GLP-1 therapy. Of 13 participants, 12 maintained or lost weight, with 6 losing additional weight. Median weight change was stable at 0.46% (~1 pound), well below the typical 5–6% rebound seen post-GLP-1 discontinuation. Revita demonstrated excellent tolerability, with ...
06-23 11:40
Fractyl Health Presents New Data at the American Diabetes Association’s 85th Scientific Sessions Demonstrating its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform Prevents Obesity and Type 2 Diabetes in Preclinical Models
Fractyl Health announced new preclinical data for its Rejuva Smart GLP-1 platform, showing that a single dose of Rejuva was well-tolerated in healthy mice and prevented weight gain and hyperglycemia when exposed to a high-fat diet. The findings highlight Rejuva's potential as a durable, one-time therapy with a favorable safety profile and superior tolerability compared to systemic GLP-1 receptor agonists. Key results include a 20% reduction in bo...
06-23 11:30
Fractyl Health Reinforces Intellectual Property Leadership in Metabolic Disease with Two New U.S. Patents Directed to Duodenal Resurfacing
Fractyl Health reinforces its leadership in metabolic disease treatments with two new U.S. patents, expanding its intellectual property portfolio to 31 granted patents. These patents cover duodenal resurfacing using thermal and non-thermal electrical energy. The company is preparing key clinical data readouts for its Revita therapy, aiming to demonstrate its potential in weight management and metabolic outcomes. Fractyl remains committed to innov...
06-18 11:00
Fractyl Health To Present Poster Of New Preclinical Data From Rejuva Smart GLP-1 Pancreatic Gene Therapy Platform At ADA 85th Scientific Sessions
Fractyl Health, Inc. (NASDAQ:GUTS) (the Company), a metabolic therapeutics company focused on pattern-breaking approaches to treat the root causes of obesity and type 2 diabetes (T2D), today announced it will present a
06-13 19:05
Fractyl Health to Present New Preclinical Data from its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform at the American Diabetes Association's 85th Scientific Sessions
Fractyl Health will present new preclinical data from its Rejuva Smart GLP-1 pancreatic gene therapy platform at the ADA's 85th Scientific Sessions in Chicago. The poster, titled "Single-Dose GLP-1–Based Pancreatic Gene Therapy Prevents Obesity and Diabetes in High-Fat–Fed Mice," will be presented on June 22, 2025, from 12:30 p.m. to 1:30 p.m. in Poster Hall F1. The Rejuva platform aims to develop gene therapies targeting the root causes of obesi...
06-13 11:00
Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita® Across its Bariatric and Metabolic Endoscopy Centers Nationwide
Fractyl Health and Bariendo Inc. have signed a non-binding Letter of Intent to explore collaboration on Fractyl's Revita procedure, an endoscopic weight maintenance solution for patients discontinuing GLP-1 drugs. Revita aims to resurface the duodenal lining to address root causes of obesity, with clinical data expected in 2025-2026. Bariendo brings a scalable platform to commercialize Revita, addressing the growing demand for long-term obesity s...
06-04 11:00
Fractyl Health Submits Clinical Trial Application in Europe
An announcement from Fractyl Health, Inc. ( ($GUTS) ) is now available. On May ...
05-19 21:47
Fractyl Health Unveils Promising Gene Therapy Data
An update from Fractyl Health, Inc. ( ($GUTS) ) is now available. On May 17, 20...
05-19 19:30
Fractyl signals accelerated enrollment for REMAIN-1 study while advancing Rejuva clinical milestones
Earnings Call Insights: Fractyl Health (GUTS) Q1 2025 Management View CEO Harith Rajagopalan stated that "2025 is poised to be a year of acceleration for Fractyl" and highlighted the completion of ful...
05-14 08:43
Fractyl Health reports Q1 results
Fractyl Health press release (NASDAQ:GUTS): Q1 Net loss was $23.7 million, compared to $3.3 million for the same period in 2024, largely due to the fluctuation in the non-cash change in fair value of ...
05-14 04:26
